OncoOne Expands Scientific Advisory Board Adding Three World-Renowned MIF and Macrophage Experts to Support Upcoming Clinical Programs
Retrieved on:
Wednesday, September 7, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Harvard Medical School, Neoplasm, University, Breast cancer, HIV disease progression rates, CEO, Division, Research, Degenerative disease, Physician, University of Louisville School of Medicine, Immune tolerance, Microbiology, Macrophage, SAB, Dana–Farber Cancer Institute, International Association for Physicians in Aesthetic Medicine, QJM, Trinity, Phenotype, Department, Homeostasis, Biochemistry, Cytokine, Trinity College, Molecular medicine, Goal, Immunology, Hospital, Leadership, MIF, Company, Publication, Tumor-associated macrophage, Lead, Association, Quarterly Journal, Molecular genetics, Society for Immunotherapy of Cancer, Society, Trinity College Dublin, Patient, Pharmaceutical industry, Vaccine, Medicine, Immunotherapy, Cancer, Brigham
oxMIF is the disease-related and druggable isoform of the macrophage migration inhibitory factor (MIF), a critical driver in innate and adaptive immunity in cancers and immunology.
Key Points:
- oxMIF is the disease-related and druggable isoform of the macrophage migration inhibitory factor (MIF), a critical driver in innate and adaptive immunity in cancers and immunology.
- The new members of the OncoOne Scientific Advisory Board include:
Dr. Seamas Donnelly is Professor of Medicine at Trinity College Dublin. - He is a global leader in translational medicine with a research focus on the development of novel compounds as anti-inflammatory/anti-cancer therapies.
- OncoOne seeks to overcome the limitations of targeting the macrophage migration inhibitory factor by harnessing the high tumor-specificity of the disease-related isoform of MIF, the oxidized macrophage migration inhibitory factor (oxMIF).